IN SILICO EVALUATION OF THE INHIBITORY POWER OF AMIDINOUREA DERIVATIVES FOR PHOSPHOPANTETHEINYL TRANSFERASE IN MYCOBACTERIUM TUBERCULOSIS
Universal Journal of Pharmaceutical Research · 15.11.2026
DOI: 10.22270/ujpr.v11i5.1665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Universal Journal of Pharmaceutical Research, online erschienen am 15.11.2026. Verfasst von Kouakou Jean-Louis Kouakou und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Tuberculosis (TB) is an infectious, contagious, and fatal disease, according to the 2025 Global Tuberculosis Report of the World Health Organization (WHO). Phosphopantetheinyl transferase (PptT) is an enzyme that acts as a catalyst in the biosynthesis of cellular lipids in Mycobacterium tuberculosis. It is considered potential target for the development of anti-tuberculosis drugs.
Methods
We used molecular docking to establish a quantitative structure-activity relationship (QSAR) model for 25 amidinourea derivatives inhibitors of PptT. The binding free energies, a key physical descriptor, enabled us to elucidate the thermodynamic factors governing the interaction between the enzyme and the inhibitor. This approach, which combines structure-based molecular docking with quantitative modeling, identified specific, critical chemical substituents. This, in turn, led to the development of new derivatives that exhibit potent antitubercular activity.
Results
The resulting QSAR model that accounts for 87% of the variation in biological activity, based on the binding free energies (BFE/PBSA) of the analogues used. Subsequently, an intuitive fragment-replacement approach, based on per-residue interaction energy, which indicates stabilizing interactions, was implemented to identify new analogues. Moreover, 200-ns molecular dynamics simulations have evaluated with satisfaction, the temporal evolution of various properties of the bound inhibitors, such as root mean square deviation (RMSD) from the initial conformation, radius of gyration (rGyr), number of intramolecular hydrogen bonds (intraHB), molecular surface area (molSA), solvent-accessible surface area (SASA), and polar surface area (PSA). The BFE/GBSA of the three best analogs, calculated over the last 50 nanoseconds of the trajectory, align with BFE/PBSA values. Finally, favorable values for the pharmacokinetic descriptors of the best analogues are obtained using the QikProp, pkCSM, and mycoCSM programs.
Conclusion
This study enabled us to identify a new amidinourea analogue AU_1-3-7-9, which is 10 times more active. Peer Review History: Received 22 July 2026; Reviewed 3 September 2026; Accepted 8 October; Available online 15 November 2026 Academic Editor: Prof. Dr. Gorkem Dulger, Duzce University, Turkey, gorkemdulger@yandex.com Reviewers: Dr. Sarfaraz Ahmed, Global Institute of Pharmaceutical Education and Research, Kashipur, Uttarakhand, India, sarfarazahmed1@gmail.com Sheima Nadim Kadhim, Deparment of Pharmacology and Toxicology, College of pharmacy, University of Basra, Iraq. ph.sheimanadim@yahoo.com
Zitieren
APA
Kouakou, K. J., Kra, K. A., Esmel, E. A., Guego, M. K., & Megnassan, E. (2026). IN SILICO EVALUATION OF THE INHIBITORY POWER OF AMIDINOUREA DERIVATIVES FOR PHOSPHOPANTETHEINYL TRANSFERASE IN MYCOBACTERIUM TUBERCULOSIS. Universal Journal of Pharmaceutical Research. https://doi.org/10.22270/ujpr.v11i5.1665
Vancouver
Kouakou KJ, Kra KA, Esmel EA, Guego MK, Megnassan E. IN SILICO EVALUATION OF THE INHIBITORY POWER OF AMIDINOUREA DERIVATIVES FOR PHOSPHOPANTETHEINYL TRANSFERASE IN MYCOBACTERIUM TUBERCULOSIS. Universal Journal of Pharmaceutical Research. 2026. doi:10.22270/ujpr.v11i5.1665
BibTeX
@article{Kouakou2026,
author = {Kouakou, Kouakou Jean-Louis and Kra, Konan Auriol and Esmel, Elvice Akori and Guego, Mélalie Kéïtaépouse and Megnassan, Eugene},
title = {IN SILICO EVALUATION OF THE INHIBITORY POWER OF AMIDINOUREA DERIVATIVES FOR PHOSPHOPANTETHEINYL TRANSFERASE IN MYCOBACTERIUM TUBERCULOSIS},
journal = {Universal Journal of Pharmaceutical Research},
year = {2026},
doi = {10.22270/ujpr.v11i5.1665}
}
EUVIMED